Raziel Announces China Market License Agreement with Fosun Pharma for RZL 012

REHOVOT, Israel, Sept. 17, 2020 /PRNewswire/ -- Raziel Therapeutics, a Pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market announces licensing of its disruptive technology, RZL-012, to Fosun Pharma for milestone payments of up to $74 million, based on development, regulatory and net sales achievements plus tiered royalties on future sales. Click here to read more


Recent Posts